Other substances

Resveratrol

A phenolic compound.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Resveratrol is a phenolic compound produced by various members of spermatophytes such as grapes, mulberry, and peanuts. It displays potential effects to suppress replication of several viruses (Yang et al., 2020).

Resveratrol on DrugBank
Resveratrol on PubChem
Resveratrol on Wikipedia

Synonyms

3,4',5-Trihydroxystilbene

C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in cultured Vero cells Small molecule In vitro	Vero cells; SARS‐CoV‐2 (BetaCoV/Shenzhen/SZTH‐003/2020 strain virus, GISAID access number: EPI_ISL_406594)	4.09	Inhibited SARS-CoV-2 infection (likely also at the level of viral entry) in non-cytotoxic concentrations in vitro.	Nov/22/2020
Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro Small molecule In vitro	Vero E6 cells; SARS-CoV-2 strain BetaCov/France	3.82	Significantly inhibited SARS-CoV-2 replication in Vero E6 cells in non-cytotoxic concentrations.	Feb/23/2021

AI-suggested references

Link	Publication date
Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections.	Jan/19/2021
Resveratrol-mediated attenuation of superantigen-driven acute respiratory distress syndrome is mediated by microbiota in the lungs and gut.	Mar/15/2021
Molecular modelling of the antiviral action of Resveratrol derivatives against the activity of two novel SARS CoV-2 and 2019-nCoV receptors.	Mar/27/2022
Effective inhibition of coronavirus replication by Polygonum cuspidatum.	May/16/2020
Potential therapeutic effects of Resveratrol against SARS-CoV-2.	Oct/11/2021
Stilbene-based natural compounds as promising drug candidates against COVID-19.	Mar/22/2022
Natural Substances and Semisynthetic Derivatives as Potential Alternative Products Against SARS-CoV-2.	Apr/11/2022
Protective Role of Combined Polyphenols and Micronutrients against Influenza A Virus and SARS-CoV-2 Infection In Vitro.	Nov/19/2021
Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.	Jul/10/2021
The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants	Sep/20/2021
Resveratrol supplementation reduces ACE2 expression in human adipose tissue	Mar/02/2022
Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors-Molecular Docking and In Vitro Study	Jul/29/2021
Sustained Release of Co-Amorphous Matrine-Type Alkaloids and Resveratrol with Anti-COVID-19 Potential	Mar/10/2022
Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease.	Sep/01/2021
Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy	Dec/01/2021
Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.	May/28/2021
Glucose-6-phosphate dehydrogenase inhibitor for treatment of severe COVID-19: Polydatin.	Mar/15/2021
ACE2 Expression Is Upregulated in Inflammatory Corneal Epithelial Cells and Attenuated by Resveratrol	Jun/24/2021
Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19	Apr/18/2021
Interference of Polydatin/Resveratrol in the ACE2:Spike Recognition during COVID-19 Infection. A Focus on Their Potential Mechanism of Action through Computational and Biochemical Assays.	Jul/16/2021
Emerging Glycation-Based Therapeutics:Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors	Feb/23/2022
Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?	May/19/2021
Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants	Jan/21/2022
Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor	May/24/2020
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer.	Jun/18/2021
Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation	Oct/05/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04799743	The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients	Recruiting	Not Applicable	Apr/01/2021	May/01/2022
Alternative id - HKCOVID19Resveratrol Interventions - Drug: Resveratrol\|Drug: Placebo capsules Study type - Interventional Study results - No Results Available Locations - Linda Zhong, Kowloon Tong, Kowloon, Hong Kong Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 30 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - The handheld basic spirometry\|PRO scores\|Borg Category-Ratio 0-10 Scale\|Lung Function Questionnaire with 6-min walk-test\|the World Health Organization Quality of Life Brief Assessment [WHOQOL-BREF (HK)]\|Body constitution questionnaires
NCT04400890	Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19	Terminated	Phase 2	Sep/12/2020	Mar/01/2021
Alternative id - McCreary2020 Interventions - Drug: Resveratrol\|Dietary Supplement: Vitamin D3 Study type - Interventional Study results - No Results Available Locations - Mt Carmel HealthSystems, Columbus, Ohio, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 100 Age - 45 Years and older (Adult, Older Adult) Outcome measures - Hospitalization rates for COVID-19\|ICU Admission Rates\|Invasive Ventilation Rates\|Pneumonia
NCT04542993	Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy	Active, not recruiting	Phase 2	Sep/08/2020	Jun/01/2022
Alternative id - SHS KAPH NSWE 20090 Interventions - Dietary Supplement: Zinc Picolinate\|Dietary Supplement: Resveratrol\|Dietary Supplement: Zinc Picolinate Placebo\|Dietary Supplement: Resveratrol Placebo Study type - Interventional Study results - No Results Available Locations - Swedish Medical Center, Seattle, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Single Group Assignment\|Masking: Single (Participant)\|Primary Purpose: Supportive Care Enrollment - 60 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Reduction in SARS-CoV-2 Viral load\|Reduction in Severity of COVID-19 Disease

Export (.csv)